Inventurus Knowledge Solutions Ltd.

“IKS is a structurally sound, founder-led subscription platform solving a durable US healthcare pain point with demonstrated operating leverage and a 2%-penetrated TAM. The moat is real but not impenetrable — ambient AI poses a genuine medium-term threat to the core clinical documentation labour model. The $557M TruBridge acquisition introduces integration risk but is de-leveraging faster than expected. The business deserves a place on every long-term investor's watchlist; it does not deserve capital at current prices. At 37x trailing earnings with probability-weighted 5-year returns below 8% CAGR, the risk/reward is unfavorable. The right entry is ~20-25% lower, around INR 1,200-1,300, where forward earnings are priced at 18-20x and the AI disruption scenario is partially absorbed.”